Vasopressin Peptide: Vasostrict, ADH Biology and ICU Use

Vasopressin is a peptide hormone with a very different profile from the research-market peptides sold online. It is a natural cyclic nonapeptide, nine amino acids long, produced in the hypothalamus and released from the posterior pituitary. It is also known as arginine vasopressin, AVP, or antidiuretic hormone, ADH. In US hospitals it is supplied as the approved injectable product Vasostrict.

The important framing is context. Vasopressin is not a wellness compound or a recovery peptide. It is a potent intravenous vasopressor and water-balance hormone used in intensive care and in specific endocrine settings. Its approved use, route, dosing and monitoring are tightly defined, and its mechanism creates real risk if it is treated casually.

This guide is educational and not medical advice. Vasopressin is a prescription medicine given under direct medical supervision, usually as a continuous intravenous infusion in critical care. It should be started, titrated, changed or stopped only by qualified clinicians.

For related clinical-peptide context, compare this guide with octreotide, icatibant, oxytocin, the overview of what peptides are, and the peptide half-life guide. Oxytocin is especially relevant because it is structurally almost identical to vasopressin, differing by only two amino acids, which helps explain why receptor selectivity matters.

Vasopressin At A Glance

How Vasopressin Works

Vasopressin acts through G protein-coupled receptors in several tissues, and its effects depend heavily on which receptor subtype is engaged.

V1a receptors sit on vascular smooth muscle. When vasopressin binds them, it activates the phospholipase C pathway, raising intracellular calcium through IP3 and DAG signaling. The result is smooth-muscle contraction and vasoconstriction. This is the mechanism that raises systemic vascular resistance and mean arterial pressure when vasopressin is used as a vasopressor. The Vasostrict label notes that at therapeutic doses in vasodilatory shock, vasopressin increases systemic vascular resistance and arterial pressure while tending to lower heart rate and cardiac output.

V2 receptors sit in the kidney's collecting ducts. There vasopressin couples to the stimulatory Gs protein, raises cyclic AMP, and activates protein kinase A. That cascade inserts aquaporin-2 water channels into the cell membrane, so the kidney reabsorbs more water and concentrates the urine. This is the antidiuretic action that gives the hormone its alternate name, ADH. V2 receptors respond at lower vasopressin concentrations than the vascular V1a receptors.

V1b receptors, sometimes called V3, are found in the anterior pituitary, where vasopressin contributes to ACTH release. This is part of the body's stress response but is not the basis for the drug's approved use.

The combination matters. A compound that constricts vessels and retains water at the same time is useful for raising blood pressure in shock, but those same actions explain the ischemia and low-sodium risks discussed below.

Approved Use And The Vasostrict Label

The modern approved product is Vasostrict, a vasopressin injection that received its initial US approval in 2014 and is marketed by Par Pharmaceutical. The labeled indication is narrow and specific: to increase blood pressure in adults with vasodilatory shock, such as post-cardiotomy or septic shock, who remain hypotensive despite fluids and catecholamines like norepinephrine.

The dose figures above come directly from the FDA label and are described here for education only. They are titration ranges used by critical-care teams with continuous monitoring, not dosing advice for any individual.

Diabetes Insipidus And The Historical Picture

Before the modern shock indication, vasopressin had a long history in endocrine medicine. Because of its V2-mediated antidiuretic action, vasopressin and the older product Pitressin were used in central diabetes insipidus, a condition where the body cannot concentrate urine because it lacks adequate ADH. The hormone was also used historically in some bleeding and abdominal-distension contexts.

For chronic central diabetes insipidus today, clinicians generally prefer desmopressin (DDAVP), a synthetic analog engineered to be more V2-selective and longer-acting, with far less V1a vasoconstrictor effect. That selectivity makes desmopressin better suited to outpatient water-balance treatment, while native vasopressin's strong pressor effect is now mainly exploited in the acute ICU setting. This split is a good example of how small changes to a peptide's structure shift its receptor profile and its clinical role.

Evidence And Its Limits

The clearest evidence supporting vasopressin is its FDA label and the critical-care trials behind its use as a vasopressor. The landmark study is the Vasopressin and Septic Shock Trial, VASST, published in the New England Journal of Medicine in 2008. It randomized 778 patients with septic shock to low-dose vasopressin (0.01 to 0.03 units per minute) added to norepinephrine, versus norepinephrine alone.

VASST did not show a statistically significant reduction in 28-day mortality overall. A prespecified subgroup with less severe shock suggested a possible survival signal, but subgroup findings are hypothesis-generating, not proof. The honest reading is that vasopressin reliably raises blood pressure and lowers catecholamine requirements, but it has not been shown to clearly improve survival across all shock patients. Later guidelines position it as an adjunct to norepinephrine rather than a replacement.

So the evidence is strong for the pharmacologic effect and the labeled indication, but more modest for hard outcomes like mortality. That distinction is exactly the kind of nuance a careful reader should expect, and it is why vasopressin is used as a targeted tool rather than a universal answer.

Safety Limits

Vasopressin's safety profile follows directly from its mechanism. The same vasoconstriction that raises blood pressure can reduce blood flow to vital tissue, and the same water reabsorption that treats diabetes insipidus can dilute sodium dangerously.

A practical pharmacology point reinforces the need for monitoring: vasopressin has a short apparent half-life, listed on the Vasostrict label as roughly ten minutes or less, because it is rapidly cleared by aminopeptidases. That short duration is why it is given as a continuous, titratable infusion rather than as bolus injections for blood-pressure support.

How To Evaluate A Vasopressin Claim

Ask a few focused questions before trusting any source on vasopressin.

First, which compound is actually meant? Native vasopressin, the Vasostrict product, the analog desmopressin and the related hormone oxytocin are different molecules with different receptor selectivity and uses.

Second, what is the setting? An ICU vasopressor indication does not translate to home use, performance use or general wellness use.

Third, does the source mention the route? Approved blood-pressure support is intravenous and monitored. A claim about subcutaneous or self-administered vasopressin for non-medical goals is a red flag.

Fourth, does it acknowledge risk? Any honest summary mentions ischemia, hyponatremia and the need for monitoring. A source that presents vasopressin as a benign peptide is skipping the core of its pharmacology.

Fifth, is label and trial evidence being used to imply unregulated human use? Borrowing the credibility of a critical-care drug to sell a research vial is a common and misleading move.

For contrast, peptides like linaclotide and teduglutide are also approved peptide drugs, but each has its own narrow indication, route and risk set. None of them are interchangeable, and the same caution applies to vasopressin.

Bottom Line

Vasopressin is a real, approved peptide hormone with a clear and important place in medicine. As the Vasostrict product, it is used intravenously to raise blood pressure in adults with vasodilatory shock who stay hypotensive despite fluids and catecholamines, and historically it has had a role in central diabetes insipidus through its antidiuretic V2 action.

The same dual mechanism that makes it useful also defines its limits. It is a potent vasoconstrictor with a short half-life, real ischemic and water-balance risks, and a narrow, monitored route of use. It is not a wellness peptide, not a self-administered compound and not something to interpret outside its label and the clinical trials behind it. Used correctly, in the right patients, under monitoring, it is a valuable tool; used loosely, it is dangerous.

References

1. DailyMed. Vasostrict (vasopressin injection) prescribing information.

2. US FDA. Vasostrict (vasopressin) full prescribing information, NDA 204485.

3. Russell JA, et al. Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock (VASST). N Engl J Med. 2008.

4. Koshimizu TA, et al. Vasopressin V1a and V1b Receptors: From Molecules to Physiological Systems. Physiol Rev. 2012.

5. Aleksandrov N, et al. Vasopressin and Vasopressin Receptor Antagonists. PMC.

6. Bankir L. Antidiuretic action of vasopressin: quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res. 2001.

7. MedlinePlus. Vasopressin Injection drug information.

8. ClinicalTrials.gov. Vasopressin and Septic Shock Trial (VASST).